Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia — PALL

Relapsed B-cell Acute Lymphoblastic Leukemia Clinical Trial

Official title:
A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia

Status Completed

Clinical Trial Summary

This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Refractory B-cell Acute Lymphoblastic Leukemia
Relapsed B-cell Acute Lymphoblastic Leukemia

Clinical Trial Details

NCT number	NCT02808442
Study type	Interventional
Source	Servier
Contact
Status	Completed
Phase	Phase 1
Start date	June 3, 2016
Completion date	November 4, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01860937` - T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia	Phase 1
Active, not recruiting	`NCT03156101` - A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects	Phase 1/Phase 2
Withdrawn	`NCT02167360` - Study of Efficacy and Safety of CTL019 in Adult ALL Patients	Phase 2
Recruiting	`NCT04556084` - Blinatumomab Bridging Therapy	Phase 2
Recruiting	`NCT06179524` - CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL	Phase 2
Completed	`NCT02228096` - Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients	Phase 2